General Information |
|
| NSE Symbol* | BLISSGVS |
| Name of the Company* | BLISS GVS PHARMA LIMITED |
| ISIN* | INE416D01022 |
| Type of Meeting |
1) Board Meeting |
| Details of Committee Meeting or Other Type of Meeting | |
| Type of Intimation* | New |
| Reason for Re-schedule (postpone or prepone) / Cancellation | |
| Proposed Meeting Date | 2025-01-28 |
| Original Meeting Date | |
| Whether trading window is closed* | Yes |
| Trading Window Closure- Start date | 2025-01-01 |
| Details of Trading Window Closure End date | 2025-01-30 |
| Short Notice | |
| Date of Report* | 2025-01-21 |
Agenda Details |
|
| Agenda* |
1) Financial results 2) Other business |
| Whether results are audited or unaudited | Unaudited |
| Nature of report standalone or consolidated | Standalone And Consolidated |
| Period end Type | Quarterly |
| Period up to (Month) | December |
| Period up to (Year) | 2024 |
| Mode of raising Funds | |
| Type of Dividend | |
| Remarks (website dissemination) | Bliss GVS Pharma Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider, approve and take on record the Unaudited (Standalone & Consolidated) Financial Results of the Company for the quarter and nine months ended December 31, 2024 and the proposal for issuance of Sweat Equity Shares pursuant to applicable provisions of the Companies Act, 2013, the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and other applicable laws and regulations to Key Managerial Personnel and/or Senior Management Personnel and/or Employee(s) of the Company including determination of the issue price if any, subject to such regulatory and statutory approvals as may be required including approval of the shareholders of the Company. |